Global Immune Checkpoint Agents Market Growth 2025-2031

Publication ID:

LPI01252417

Publication Date:

January 28, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Immune Checkpoint Agents market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
Immune Checkpoint Agents are a class of drugs used in cancer treatment that help the body fight cancer cells by modulating the function of the immune system. Immune checkpoints are biological mechanisms that help maintain the balance of the immune system and prevent it from attacking normal cells. However, some cancer cells can use this mechanism to evade immune system attack.
United States market for Immune Checkpoint Agents is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Immune Checkpoint Agents is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Immune Checkpoint Agents is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Immune Checkpoint Agents players cover Bristol Myers Squibb, Merck, AstraZeneca, Roche, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淚mmune Checkpoint Agents Industry Forecast鈥� looks at past sales and reviews total world Immune Checkpoint Agents sales in 2024, providing a comprehensive analysis by region and market sector of projected Immune Checkpoint Agents sales for 2025 through 2031. With Immune Checkpoint Agents sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Immune Checkpoint Agents industry.
This Insight Report provides a comprehensive analysis of the global Immune Checkpoint Agents landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Immune Checkpoint Agents portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Immune Checkpoint Agents market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Immune Checkpoint Agents and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Immune Checkpoint Agents.
This report presents a comprehensive overview, market shares, and growth opportunities of Immune Checkpoint Agents market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Anti-PD-L1 Drug
Anti-PD-1 Drug
CTLA4
Segmentation by Application:
Lung Cancer
Colorectal Cancer
BreastCancer
Prostate Cancer
Melanoma
Blood Cancers
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Bristol Myers Squibb
Merck
AstraZeneca
Roche
Key Questions Addressed in this Report
What is the 10-year outlook for the global Immune Checkpoint Agents market?
What factors are driving Immune Checkpoint Agents market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Immune Checkpoint Agents market opportunities vary by end market size?
How does Immune Checkpoint Agents break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Immune Checkpoint Agents Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Immune Checkpoint Agents by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Immune Checkpoint Agents by Country/Region, 2020, 2024 & 2031
2.2 Immune Checkpoint Agents Segment by Type
2.2.1 Anti-PD-L1 Drug
2.2.2 Anti-PD-1 Drug
2.2.3 CTLA4
2.3 Immune Checkpoint Agents Sales by Type
2.3.1 Global Immune Checkpoint Agents Sales Market Share by Type (2020-2025)
2.3.2 Global Immune Checkpoint Agents Revenue and Market Share by Type (2020-2025)
2.3.3 Global Immune Checkpoint Agents Sale Price by Type (2020-2025)
2.4 Immune Checkpoint Agents Segment by Application
2.4.1 Lung Cancer
2.4.2 Colorectal Cancer
2.4.3 BreastCancer
2.4.4 Prostate Cancer
2.4.5 Melanoma
2.4.6 Blood Cancers
2.5 Immune Checkpoint Agents Sales by Application
2.5.1 Global Immune Checkpoint Agents Sale Market Share by Application (2020-2025)
2.5.2 Global Immune Checkpoint Agents Revenue and Market Share by Application (2020-2025)
2.5.3 Global Immune Checkpoint Agents Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Immune Checkpoint Agents Breakdown Data by Company
3.1.1 Global Immune Checkpoint Agents Annual Sales by Company (2020-2025)
3.1.2 Global Immune Checkpoint Agents Sales Market Share by Company (2020-2025)
3.2 Global Immune Checkpoint Agents Annual Revenue by Company (2020-2025)
3.2.1 Global Immune Checkpoint Agents Revenue by Company (2020-2025)
3.2.2 Global Immune Checkpoint Agents Revenue Market Share by Company (2020-2025)
3.3 Global Immune Checkpoint Agents Sale Price by Company
3.4 Key Manufacturers Immune Checkpoint Agents Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Immune Checkpoint Agents Product Location Distribution
3.4.2 Players Immune Checkpoint Agents Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Immune Checkpoint Agents by Geographic Region
4.1 World Historic Immune Checkpoint Agents Market Size by Geographic Region (2020-2025)
4.1.1 Global Immune Checkpoint Agents Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Immune Checkpoint Agents Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Immune Checkpoint Agents Market Size by Country/Region (2020-2025)
4.2.1 Global Immune Checkpoint Agents Annual Sales by Country/Region (2020-2025)
4.2.2 Global Immune Checkpoint Agents Annual Revenue by Country/Region (2020-2025)
4.3 Americas Immune Checkpoint Agents Sales Growth
4.4 APAC Immune Checkpoint Agents Sales Growth
4.5 Europe Immune Checkpoint Agents Sales Growth
4.6 Middle East & Africa Immune Checkpoint Agents Sales Growth
5 Americas
5.1 Americas Immune Checkpoint Agents Sales by Country
5.1.1 Americas Immune Checkpoint Agents Sales by Country (2020-2025)
5.1.2 Americas Immune Checkpoint Agents Revenue by Country (2020-2025)
5.2 Americas Immune Checkpoint Agents Sales by Type (2020-2025)
5.3 Americas Immune Checkpoint Agents Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Immune Checkpoint Agents Sales by Region
6.1.1 APAC Immune Checkpoint Agents Sales by Region (2020-2025)
6.1.2 APAC Immune Checkpoint Agents Revenue by Region (2020-2025)
6.2 APAC Immune Checkpoint Agents Sales by Type (2020-2025)
6.3 APAC Immune Checkpoint Agents Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Immune Checkpoint Agents by Country
7.1.1 Europe Immune Checkpoint Agents Sales by Country (2020-2025)
7.1.2 Europe Immune Checkpoint Agents Revenue by Country (2020-2025)
7.2 Europe Immune Checkpoint Agents Sales by Type (2020-2025)
7.3 Europe Immune Checkpoint Agents Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Immune Checkpoint Agents by Country
8.1.1 Middle East & Africa Immune Checkpoint Agents Sales by Country (2020-2025)
8.1.2 Middle East & Africa Immune Checkpoint Agents Revenue by Country (2020-2025)
8.2 Middle East & Africa Immune Checkpoint Agents Sales by Type (2020-2025)
8.3 Middle East & Africa Immune Checkpoint Agents Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Immune Checkpoint Agents
10.3 Manufacturing Process Analysis of Immune Checkpoint Agents
10.4 Industry Chain Structure of Immune Checkpoint Agents
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Immune Checkpoint Agents Distributors
11.3 Immune Checkpoint Agents Customer
12 World Forecast Review for Immune Checkpoint Agents by Geographic Region
12.1 Global Immune Checkpoint Agents Market Size Forecast by Region
12.1.1 Global Immune Checkpoint Agents Forecast by Region (2026-2031)
12.1.2 Global Immune Checkpoint Agents Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Immune Checkpoint Agents Forecast by Type (2026-2031)
12.7 Global Immune Checkpoint Agents Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Bristol Myers Squibb
13.1.1 Bristol Myers Squibb Company Information
13.1.2 Bristol Myers Squibb Immune Checkpoint Agents Product Portfolios and Specifications
13.1.3 Bristol Myers Squibb Immune Checkpoint Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Bristol Myers Squibb Main Business Overview
13.1.5 Bristol Myers Squibb Latest Developments
13.2 Merck
13.2.1 Merck Company Information
13.2.2 Merck Immune Checkpoint Agents Product Portfolios and Specifications
13.2.3 Merck Immune Checkpoint Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Merck Main Business Overview
13.2.5 Merck Latest Developments
13.3 AstraZeneca
13.3.1 AstraZeneca Company Information
13.3.2 AstraZeneca Immune Checkpoint Agents Product Portfolios and Specifications
13.3.3 AstraZeneca Immune Checkpoint Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 AstraZeneca Main Business Overview
13.3.5 AstraZeneca Latest Developments
13.4 Roche
13.4.1 Roche Company Information
13.4.2 Roche Immune Checkpoint Agents Product Portfolios and Specifications
13.4.3 Roche Immune Checkpoint Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Roche Main Business Overview
13.4.5 Roche Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂